Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2,318.9 | 2,993.2 | 2,903.1 | 2,914.4 | 2,947.1 | 3,468.9 | 4,010.3 | 3,268.7 |
| Revenue growth | -22.5% | 3.1% | -0.4% | -1.1% | -15.0% | -13.5% | 22.7% | 37.3% |
| Cost of goods sold | 1,092.5 | 1,221.1 | 1,442.5 | 1,569.3 | 1,631.7 | 2,228.5 | 2,635.0 | 2,075.7 |
| Gross profit | 1,226.4 | 1,772.1 | 1,460.6 | 1,345.0 | 1,315.4 | 1,240.3 | 1,375.3 | 1,193.1 |
| Gross margin | 52.9% | 59.2% | 50.3% | 46.2% | 44.6% | 35.8% | 34.3% | 36.5% |
| Selling, general and administrative | 777.2 | 861.8 | 698.5 | 632.4 | 646.0 | 629.9 | 770.7 | 741.3 |
| Research and development | 128.0 | 123.4 | 125.6 | 130.7 | 185.8 | 172.1 | 183.4 | 102.2 |
| EBITA | 455.5 | 759.4 | 636.5 | 810.3 | 1,092.0 | 956.8 | 1,297.7 | 910.9 |
| EBITA margin | 19.6% | 25.4% | 21.9% | 27.8% | 37.1% | 27.6% | 32.4% | 27.9% |
| Amortization of intangibles | 337.3 | | | | 622.3 | 773.8 | 876.5 | 561.3 |
| EBIT | 118.2 | 759.4 | 636.5 | 810.3 | 469.7 | 183.0 | 421.2 | 349.6 |
| EBIT margin | 5.1% | 25.4% | 21.9% | 27.8% | 15.9% | 5.3% | 10.5% | 10.7% |
| Pre-tax income | -2,888.1 | -546.6 | -26.5 | -344.9 | -938.8 | -1,483.0 | -3,923.9 | -1,437.9 |
| Income taxes | 21.5 | 22.5 | -274.0 | 15.7 | 22.9 | -250.3 | -700.1 | -1,137.5 |
| Tax rate | | | 1033.2% | | | 16.9% | 17.8% | 79.1% |
| Earnings from continuing ops | -2,909.6 | -569.1 | 247.5 | -360.6 | -961.8 | -1,232.7 | -3,223.8 | -300.1 |
| Earnings from discontinued ops | | | | | | | -123.3 | -1,194.9 |
| Net income | -2,923.1 | -613.2 | 183.9 | -422.6 | -1,031.5 | -2,035.4 | -3,347.1 | -1,495.0 |
| Net margin | -126.1% | -20.5% | 6.3% | -14.5% | -35.0% | -58.7% | -83.5% | -45.7% |
| |
| Diluted EPS | ($12.39) | ($2.44) | $1.06 | ($1.60) | ($4.29) | ($5.52) | ($14.48) | ($1.52) |
| Shares outstanding (diluted) | 234.8 | 232.8 | 233.7 | 226.1 | 224.0 | 223.2 | 222.7 | 197.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|